[go: up one dir, main page]

EP1499277A4 - CHANGE OF THE ESSENCE - Google Patents

CHANGE OF THE ESSENCE

Info

Publication number
EP1499277A4
EP1499277A4 EP02768992A EP02768992A EP1499277A4 EP 1499277 A4 EP1499277 A4 EP 1499277A4 EP 02768992 A EP02768992 A EP 02768992A EP 02768992 A EP02768992 A EP 02768992A EP 1499277 A4 EP1499277 A4 EP 1499277A4
Authority
EP
European Patent Office
Prior art keywords
subject
essence
change
decreasing
intake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02768992A
Other languages
German (de)
French (fr)
Other versions
EP1499277B1 (en
EP1499277A2 (en
Inventor
Michael Cowley
Roger Cone
Malcolm Low
Andrew Butler
Stephen R Bloom
Caroline J Small
Rachael L Batterham
Mohammad Ali Ghatei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Oregon Health and Science University
Original Assignee
Imperial College Innovations Ltd
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0200507.2A external-priority patent/GB0200507D0/en
Application filed by Imperial College Innovations Ltd, Oregon Health and Science University filed Critical Imperial College Innovations Ltd
Priority to EP20080022583 priority Critical patent/EP2050460A1/en
Publication of EP1499277A2 publication Critical patent/EP1499277A2/en
Publication of EP1499277A4 publication Critical patent/EP1499277A4/en
Application granted granted Critical
Publication of EP1499277B1 publication Critical patent/EP1499277B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Liquid Developers In Electrophotography (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Lasers (AREA)
  • Toilet Supplies (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Fats And Perfumes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.
EP02768992A 2001-09-24 2002-09-24 Pyy3-36 for the reduction or prevention of obesity Expired - Lifetime EP1499277B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20080022583 EP2050460A1 (en) 2001-09-24 2002-09-24 PYY and agonists thereof for modification of feeding behaviour

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32440601P 2001-09-24 2001-09-24
US324406P 2001-09-24
GB0200507 2002-01-10
GBGB0200507.2A GB0200507D0 (en) 2002-01-10 2002-01-10 Appetite suppression
US39210902P 2002-06-28 2002-06-28
US392109P 2002-06-28
PCT/US2002/031944 WO2003026591A2 (en) 2001-09-24 2002-09-24 Modification of feeding behavior

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP20080022583 Division EP2050460A1 (en) 2001-09-24 2002-09-24 PYY and agonists thereof for modification of feeding behaviour

Publications (3)

Publication Number Publication Date
EP1499277A2 EP1499277A2 (en) 2005-01-26
EP1499277A4 true EP1499277A4 (en) 2005-08-31
EP1499277B1 EP1499277B1 (en) 2009-01-07

Family

ID=27256373

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02768992A Expired - Lifetime EP1499277B1 (en) 2001-09-24 2002-09-24 Pyy3-36 for the reduction or prevention of obesity
EP20080022583 Withdrawn EP2050460A1 (en) 2001-09-24 2002-09-24 PYY and agonists thereof for modification of feeding behaviour

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20080022583 Withdrawn EP2050460A1 (en) 2001-09-24 2002-09-24 PYY and agonists thereof for modification of feeding behaviour

Country Status (19)

Country Link
US (2) US7459432B2 (en)
EP (2) EP1499277B1 (en)
JP (3) JP2005508324A (en)
KR (1) KR100989647B1 (en)
CN (1) CN100350968C (en)
AT (1) ATE419863T1 (en)
AU (1) AU2002332054B2 (en)
BR (1) BR0212985A (en)
CA (1) CA2461345A1 (en)
DE (1) DE60230818D1 (en)
DK (1) DK1499277T3 (en)
ES (1) ES2320979T3 (en)
HK (1) HK1070281A1 (en)
HU (1) HU228621B1 (en)
IL (3) IL160983A0 (en)
MX (1) MXPA04002751A (en)
NZ (1) NZ532427A (en)
PL (1) PL205971B1 (en)
WO (1) WO2003026591A2 (en)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
JP2003518914A (en) 1999-02-10 2003-06-17 キュリス インコーポレイテッド Methods and reagents for treating glucose metabolism disorders
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
ATE450269T1 (en) 2000-12-14 2009-12-15 Amylin Pharmaceuticals Inc PEPTIDE PYYÄ3-36Ü FOR THE TREATMENT OF METABOLIC DISEASES
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP1585956A4 (en) 2001-09-24 2009-10-21 Univ Oregon Health & Science EVALUATION OF NEURONS IN THE NUCLEUS ARCUATUS FOR SCREENING ON THE ESSENTIAL CHANGING SUBSTANCES
MXPA04002751A (en) 2001-09-24 2005-09-08 Univ Oregon Health & Science Modification of feeding behavior.
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004056314A2 (en) 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1964630A (en) 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
KR20060070572A (en) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Novel Heterocyclic Compounds as HPS90-Inhibitors
EP2422806A3 (en) 2004-02-11 2012-06-13 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
JP5638177B2 (en) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc Pancreatic polypeptide family motif and polypeptide containing the motif
WO2005080424A2 (en) * 2004-02-23 2005-09-01 Rheoscience A/S Peptide yy analogues
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
GB0411014D0 (en) * 2004-05-18 2004-06-23 Haptogen Ltd Methods for the control treatment and management of obesity
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
CN105708787A (en) * 2004-07-12 2016-06-29 爱密斯菲尔科技公司 Compositions for delivering peptide yy and pyy agonists
AU2005291359B2 (en) * 2004-10-07 2011-10-13 Nestec S.A. Bioactive compositions, natural methods of producing them and computational methods for designing natural production processes
WO2006042242A2 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them
NZ555464A (en) 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
KR101272402B1 (en) 2004-12-13 2013-06-10 아스트라제네카 파마수티컬스 엘피 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
PA8660701A1 (en) 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
SG159551A1 (en) 2005-02-11 2010-03-30 Amylin Pharmaceuticals Inc Gip analog and hybrid polypeptides with selectable properties
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
AU2005337101A1 (en) * 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
BRPI0520563A2 (en) 2005-09-21 2009-05-19 7Tm Pharma As selective y4 receptor agonists for therapeutic interventions
CN101277960A (en) 2005-09-29 2008-10-01 默克公司 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007039318A2 (en) * 2005-10-06 2007-04-12 Bayer Schering Pharma Aktiengesellschaft Neuropeptide y analogs
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
WO2007085887A1 (en) * 2006-01-27 2007-08-02 Pfizer Products Inc. Pyy agonists and uses thereof
JP5143131B2 (en) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド Two-piece internal channel flow modulator for osmotic delivery system
US8977517B2 (en) * 2006-06-05 2015-03-10 Creighton University System and methods for evaluating efficacy of appetite-affecting drugs
GB0613196D0 (en) * 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JP5048773B2 (en) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド Osmotic delivery system and piston assembly
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
TWI428346B (en) * 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
RU2440097C2 (en) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7814038B1 (en) * 2007-12-06 2010-10-12 Dominic John Repici Feedback-tolerant method and device producing weight-adjustment factors for pre-synaptic neurons in artificial neural networks
US9938333B2 (en) * 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010090876A2 (en) 2009-01-21 2010-08-12 University Of Florida Research Foundation, Inc. Satiation peptide administration
WO2011002066A1 (en) * 2009-07-02 2011-01-06 武田薬品工業株式会社 Peptide and use thereof
US8298561B2 (en) 2009-09-28 2012-10-30 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
GB201001333D0 (en) 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3326620B1 (en) 2010-12-16 2020-03-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012220595B2 (en) 2011-02-25 2015-07-16 Merck Sharp & Dohme Llc Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AP2013007180A0 (en) 2011-04-25 2013-10-31 Advanced Bioscience Lab Inc Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
SMT201800491T1 (en) 2012-03-22 2018-11-09 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
JP2015525782A (en) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic tricyclic compounds
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme BICYCLIC ANTIDIABETIC COMPOUNDS
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10017554B2 (en) 2013-04-10 2018-07-10 University Of Copenhagen Neuropeptide Y-derived peptides
CA2909045C (en) * 2013-05-02 2022-12-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
ES2688462T3 (en) 2013-05-02 2018-11-02 Novo Nordisk A/S Oral dosage of GLP-1 compounds
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN113388007A (en) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 Ultra-pure agonists of guanylate cyclase C, methods of making and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2929672A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
CN105764919B (en) 2013-11-15 2021-04-27 诺和诺德股份有限公司 hPYY(1-36) with β-homoarginine substitution at position 35
US20170137486A1 (en) 2014-05-23 2017-05-18 Imperial Innovations Limited Peptide yy (pyy) analogues
RU2021109549A (en) 2014-08-29 2021-05-13 Тес Фарма С.Р.Л. Α-AMINO-β-CARBOXYMUCONATE INHIBITORS of ε-SEMIALDEHYDE-DECARBOXYLASE
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017015504A (en) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Implant placement and removal systems.
MA43205A (en) 2015-06-12 2018-09-19 Novo Nordisk As SELECTIVE PYY COMPOUNDS AND THEIR USES
KR101604212B1 (en) * 2015-07-17 2016-03-17 울산대학교 산학협력단 Composition for the prevention and treatment of obesity or impaired glucose tolerance containing NAD
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
LT3393655T (en) 2015-12-22 2021-03-25 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
US11311633B2 (en) 2016-04-16 2022-04-26 University Of Florida Research Foundation, Incorporated Satiation peptides for weight loss and altered taste sensitivity
TWI754643B (en) 2016-05-16 2022-02-11 美商因塔希亞治療公司 Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
BR112019007543A2 (en) 2016-10-14 2019-07-02 Tes Pharma S R L alpha-amino-beta-carboximuconic acid inhibitors semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US12240890B2 (en) * 2017-05-16 2025-03-04 The University Of Chicago Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
KR20200132852A (en) * 2018-01-23 2020-11-25 길라 테라퓨틱스, 인코포레이티드 Peptide YY pharmaceutical formulations, compositions, and methods
MA53076B1 (en) 2018-02-02 2023-11-30 Novo Nordisk As SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLATE ACID SALT AND A LUBRICANT
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN113092427A (en) * 2021-04-02 2021-07-09 南京中医药大学 Application of fluorescein isothiocyanate in marking beta endorphin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047219A2 (en) * 1999-02-10 2000-08-17 Ontogeny, Inc. Methods and reagents for treating glucose metabolic disorders
WO2001076631A2 (en) * 2000-04-10 2001-10-18 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
WO2002047712A2 (en) * 2000-12-14 2002-06-20 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4223017A (en) 1975-04-15 1980-09-16 Burroughs Wellcome Co. Biologically active amides
GB1560933A (en) 1975-04-15 1980-02-13 Wellcome Found Biologically activy polypeptides
US4175122A (en) 1975-04-15 1979-11-20 Burroughs Wellcome Co. Biologically active amides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4220653A (en) * 1979-01-24 1980-09-02 Vivino A Earl Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight
US4229389A (en) 1979-03-16 1980-10-21 Thompson Marine Corporation Gas diffuser, aerator, or sparger apparatus
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (en) 1982-01-06 1983-07-13 Nec Corp Data processor
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (en) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd Method for producing liposomes
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0142641B1 (en) * 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Means and product for the diagnosis and therapy of tumours and for the treatment of weaknesses of the cellular and humoral immune system
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4701441A (en) 1985-02-11 1987-10-20 University Of Florida Methods and compositions for stimulation of appetite
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
HU196755B (en) 1986-09-16 1989-01-30 Gyogyszerkutato Intezet Process for production of new substituated amilid derivatives and medical compositions containing them
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
AU633011B2 (en) 1988-06-28 1993-01-21 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5026685A (en) 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE9002278L (en) 1990-06-28 1991-12-29 Perstorp Ab APPLICATION OF INOSITOL TRISPHOSPHATE FOR THE PREPARATION OF A MEDICINE
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
CA2123108C (en) 1991-11-06 2003-03-25 Lisa Selbie Human neuropeptide y-y1 receptor
DK39892D0 (en) 1992-03-25 1992-03-25 Bernard Thorens PEPTIDE
WO1994010220A1 (en) 1992-10-28 1994-05-11 Kuraray Co., Ltd. Polyurethane and leatherlike sheet made therefrom
JP2961045B2 (en) * 1993-02-24 1999-10-12 日清製粉株式会社 Intestinal mucosa enhancement promoter
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5545549A (en) 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
CA2204645A1 (en) 1994-11-07 1996-05-17 Keiichi Yano Novel oxyntomodulin
EP0791009A4 (en) 1994-11-07 2003-03-05 Merck & Co Inc Modified neuropeptide y receptors
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5912227A (en) * 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US5668151A (en) 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
DK1238659T3 (en) 1996-02-02 2005-01-24 Alza Corp Sustained release of an active agent using an implantable system
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US5919901A (en) 1996-04-08 1999-07-06 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE122009000079I2 (en) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle GLP-1 DERIVATIVES
UA65549C2 (en) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
ES2290799T3 (en) 1996-11-12 2008-02-16 Novo Nordisk A/S USE OF GLP-1 PEPTIDES.
JP2000505105A (en) 1996-11-13 2000-04-25 ユニヴァーシティ・オブ・シンシナティ Analogs of peptide YY and uses thereof
PT1629849E (en) * 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exendins and agonists thereof
DE69800640T2 (en) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London PEGYLATION PROCEDURE
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
US5889016A (en) 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
EP2574336A1 (en) * 1998-02-02 2013-04-03 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
FR2774674B1 (en) 1998-02-10 2000-03-24 Atochem Elf Sa PROCESS FOR THE PREPARATION OF AN AQUEOUS SOLUTION OF HYDROGEN PEROXIDE DIRECTLY FROM HYDROGEN AND OXYGEN AND DEVICE FOR IMPLEMENTING SAME
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
FR2777283B1 (en) 1998-04-10 2000-11-24 Adir NOVEL GLUCAGON-PEPTIDE- 1 (7-37) ANALOGUE PEPTIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
ATE269846T1 (en) 1998-04-29 2004-07-15 Ortho Mcneil Pharm Inc N-SUBSTITUTED AMINOTETRALINES AS NEUROPEPTIDE Y Y5 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF OBESITY AND OTHER DISEASES
CN1329589A (en) 1998-10-07 2002-01-02 奥索-麦克尼尔药品公司 N-aralkylaminotetralins as ligands for neuroptide YY5 receptor
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
WO2000059887A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
CA2373035A1 (en) 1999-05-05 2000-11-16 Scott Dax 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
PT1133312E (en) 1999-06-21 2007-11-30 Lilly Co Eli Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
NZ516782A (en) 1999-07-28 2004-12-24 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
CA2382528A1 (en) * 1999-08-25 2001-03-01 Banyu Pharmaceutical Co., Ltd. Novel isoindole derivatives
CA2381111A1 (en) 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
AU6798000A (en) 1999-08-26 2001-03-19 Viropharma Incorporated Compounds, compositions and methods for treating influenza
YU23802A (en) 1999-09-30 2004-09-03 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo/1,5-a/1,5- pyrimidines and pyrazolo/1,5-a/-1,3,5-triazines
EP1239871A1 (en) 1999-11-12 2002-09-18 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US6699891B1 (en) * 1999-11-26 2004-03-02 Shionogi & Co., Ltd. Npyy5 antagonists
EP1246638B2 (en) 2000-01-10 2014-07-30 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of hypertriglyceridemia
EP1263458B1 (en) 2000-03-08 2005-11-16 Novo Nordisk A/S Lowering serum cholesterol
WO2001068699A2 (en) 2000-03-16 2001-09-20 Bayer Aktiengesellschaft Regulation of human neuropeptide y-like g protein-coupled receptor
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
EP1286697A2 (en) 2000-05-17 2003-03-05 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US6256216B1 (en) * 2000-05-18 2001-07-03 Integrated Device Technology, Inc. Cam array with minimum cell size
WO2001089554A2 (en) 2000-05-19 2001-11-29 Bionebraska, Inc. Treatment of acute coronary syndrome with glp-1
US6391881B2 (en) 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
IL153513A0 (en) 2000-07-06 2003-07-06 Metabasis Therapeutics Inc A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US20020156010A1 (en) * 2000-11-20 2002-10-24 Lustig Robert H. Method of treating obesity in adult patients exhibiting primary insulin hypersecretion
WO2002066479A1 (en) 2001-02-23 2002-08-29 Banyu Pharmaceutical Co.,Ltd. Novel isoindole derivatives
WO2002067918A1 (en) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Novel diallylmethylamine derivative
AU2002355286B2 (en) * 2001-07-26 2005-10-13 Schering Corporation Substituted urea neuropeptide Y Y5 receptor antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
MXPA04002751A (en) 2001-09-24 2005-09-08 Univ Oregon Health & Science Modification of feeding behavior.
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
PL1620118T3 (en) * 2003-04-08 2014-11-28 Yeda Res & Dev Reversible pegylated drugs
CN1220702C (en) 2003-07-30 2005-09-28 北京中科亚光生物科技有限公司 Insulinotropic peptide and its use
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
EP2740743A3 (en) 2004-06-01 2015-08-19 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
PA8660701A1 (en) 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2008543816A (en) 2005-06-13 2008-12-04 インペリアル イノベーションズ リミテッド Novel compounds and their effects on eating behavior
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047219A2 (en) * 1999-02-10 2000-08-17 Ontogeny, Inc. Methods and reagents for treating glucose metabolic disorders
WO2001076631A2 (en) * 2000-04-10 2001-10-18 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
WO2002047712A2 (en) * 2000-12-14 2002-06-20 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATTERHAM R L ET AL: "Gut hormone PYY3-36 physiologically inhibits food intake", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 418, 8 August 2002 (2002-08-08), pages 650 - 654, XP002984562, ISSN: 0028-0836 *
CLAPHAM J C ET AL: "ANTI-OBESITY DRUGS: A CRITICAL REVIEW OF CURRENT THERAPIES AND FUTURE OPPORTUNITIES", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 89, no. 1, January 2001 (2001-01-01), pages 81 - 121, XP001120530, ISSN: 0163-7258 *
ROSSI M ET AL: "Central nervous system neuropeptides involved in obesity.", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 149, 2000, 2000 Springer-Verlag GmbH & Co. KG;Springer-Verlag New York Inc. Heidelberger Platz 3, D-14197, Berlin, Germany; 175 Fifth Avenue, New York, NY, 10010-7858, USA, pages 313 - 341, XP001154661, ISSN: 0171-2004 *

Also Published As

Publication number Publication date
US20090209461A1 (en) 2009-08-20
HK1070281A1 (en) 2005-06-17
EP1499277B1 (en) 2009-01-07
HUP0600337A3 (en) 2011-03-28
WO2003026591A3 (en) 2004-10-28
PL374270A1 (en) 2005-10-03
CA2461345A1 (en) 2003-04-03
HU228621B1 (en) 2013-04-29
WO2003026591A9 (en) 2004-07-08
US20050176630A1 (en) 2005-08-11
EP1499277A2 (en) 2005-01-26
IL199364A (en) 2012-02-29
MXPA04002751A (en) 2005-09-08
IL199364A0 (en) 2011-07-31
AU2002332054B2 (en) 2007-11-08
KR100989647B1 (en) 2010-10-26
JP2010111694A (en) 2010-05-20
JP6124565B2 (en) 2017-05-10
CN1596119A (en) 2005-03-16
JP2005508324A (en) 2005-03-31
US8217001B2 (en) 2012-07-10
HUP0600337A2 (en) 2006-08-28
US7459432B2 (en) 2008-12-02
EP2050460A1 (en) 2009-04-22
CN100350968C (en) 2007-11-28
ATE419863T1 (en) 2009-01-15
KR20090122497A (en) 2009-11-30
IL160983A (en) 2010-11-30
IL160983A0 (en) 2004-08-31
BR0212985A (en) 2005-08-30
JP2013047275A (en) 2013-03-07
NZ532427A (en) 2008-07-31
ES2320979T3 (en) 2009-06-01
WO2003026591A2 (en) 2003-04-03
DK1499277T3 (en) 2009-05-11
PL205971B1 (en) 2010-06-30
DE60230818D1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
EP1499277A4 (en) CHANGE OF THE ESSENCE
WO2003057235A3 (en) Modification of feeding behavior
IS7814A (en) Phenethanolamine derivatives in the treatment of respiratory diseases.
IL176758A0 (en) 1,3-dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes
DK1656827T3 (en) Combine harvester with straw
WO2004005326A3 (en) Tubulysin conjugates
ITRM20020042V0 (en) MODULAR HANDLE PERFECTED, IN PARTICULAR HANDLE FOR PURPOSES AND SIMILAR.
EP1539153A4 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
BR0314139A (en) Substituted 1,4-pyrazine derivatives
AU2003289925A1 (en) Copolymers based on n-vinylamide as adjuvants and agents for using in the agrotechnical field
BR0313665A (en) Bupropion for the treatment of restless leg syndrome
ITRM20030485A0 (en) COMPOSITION BASED ON CITICHOLINE IN ASSOCIATION WITH VITAMINS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES.
EP1497307A4 (en) VACCINE WITH RECOMBINANT P.FALCIPARUM-MEROZOITPROTEIN-1 42
USD562460S1 (en) Orthopedic bench
AU2003214701A1 (en) Mattress with adjustable hardness
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
USD506228S1 (en) Game
DE10256371A8 (en) Tobacco preparation device
FR2834625B1 (en) ADJUSTABLE OR SIMILAR ARMCHAIR
SE0101870D0 (en) Mattress with adjustable hardness
ITRM20020023U1 (en) CUSTOMIZED KNOB FOR MOTORCYCLES AND MOTORCYCLES.
BR0200885A (en) Adjustable skate
ES1053210U (en) Cube pedal perfected (Machine-translation by Google Translate, not legally binding)
GB0212031D0 (en) IL-11 Derivatives and therapeutical uses thereof
ES1047969Y (en) BARBECUE OF WOOD OR PERFECTED CARBON.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040407

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070281

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20050719

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/22 A

Ipc: 7A 61P 3/04 B

17Q First examination report despatched

Effective date: 20060327

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OREGON HEALTH AND SCIENCE UNIVERSITY

Owner name: IMPERIAL INNOVATIONS LIMITED

17Q First examination report despatched

Effective date: 20060327

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RTI1 Title (correction)

Free format text: PYY3-36 FOR THE REDUCTION OR PREVENTION OF OBESITY

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60230818

Country of ref document: DE

Date of ref document: 20090226

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2320979

Country of ref document: ES

Kind code of ref document: T3

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20090107

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1070281

Country of ref document: HK

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE S.A.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090608

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090107

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090107

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090107

26N No opposition filed

Effective date: 20091008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090924

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090107

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20130925

Year of fee payment: 12

Ref country code: FI

Payment date: 20130927

Year of fee payment: 12

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20140930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140924

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20150929

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20150929

Year of fee payment: 14

Ref country code: BE

Payment date: 20150928

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20150926

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160925

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20161001

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160924

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20170925

Year of fee payment: 16

Ref country code: FR

Payment date: 20170925

Year of fee payment: 16

Ref country code: GB

Payment date: 20170927

Year of fee payment: 16

Ref country code: CH

Payment date: 20170927

Year of fee payment: 16

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20160930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170927

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20171002

Year of fee payment: 16

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60230818

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180924

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180924

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180924

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20191104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180925